Aacr 2022 Arima Genomics Arima genomics provides 3d genomic technologies that enable researchers to uncover novel disease mechanisms and identify new therapeutic targets. join us to learn how spatial and temporal changes in dna organization impact tumorigenesis. To address these limitations, we developed a novel approach to identifying gene fusions from ffpe samples using the arima hic platform and short read sequencing. we performed pan cancer analysis on 12 ffpe adult tumor biopsies, each with gene fusions known to be clinically actionable.
Resource Download Aacr 2022 Poster All meetings and workshops held in 2022 will be listed here with links to the program and abstracts when available. In 2022, aacr held the first ever sessions in pre cancer discovery and tumor evolution—emerging foci that will allow the identification of cells most likely to become cancerous or metastasize. several presenters—including bcrf investigators—summarized current progress in these areas. We also announced our cancer research grant program, enabling researchers to apply for a free arima genomics kit to power their exploration of cancer genomics. applications close may 4, 2022. Attend these presentations during the aacr annual meeting 2022 to see how ngs is advancing oncology research detection of gene fusions and exon skipping events in lung ffpe samples with the oncominetm precision assay on the ion torrenttm genexustm system number: 78 | board 15 presenter: amir marcovitz session title: cancer genomics 2.
Arima Genomics Announces Upcoming Poster Presentation At The American We also announced our cancer research grant program, enabling researchers to apply for a free arima genomics kit to power their exploration of cancer genomics. applications close may 4, 2022. Attend these presentations during the aacr annual meeting 2022 to see how ngs is advancing oncology research detection of gene fusions and exon skipping events in lung ffpe samples with the oncominetm precision assay on the ion torrenttm genexustm system number: 78 | board 15 presenter: amir marcovitz session title: cancer genomics 2. The aacr annual meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. In a plenary session on decoding cancer health disparities, cheryl willman described her experiences in promoting participation in cancer genome sequencing initiatives among citizens of native. In summary, this study demonstrates how arima hic sequencing provides molecular diagnostic value in archived pediatric solid and liquid tumor specimens via the identification of clinically relevant gene fusions. Arima genomics is redefining cancer diagnostics using whole genome sequence and structure information. we are enabling a new era of comprehensive, clinically actionable therapy selection insight.
Arima Genomics Inform Solutions The aacr annual meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. In a plenary session on decoding cancer health disparities, cheryl willman described her experiences in promoting participation in cancer genome sequencing initiatives among citizens of native. In summary, this study demonstrates how arima hic sequencing provides molecular diagnostic value in archived pediatric solid and liquid tumor specimens via the identification of clinically relevant gene fusions. Arima genomics is redefining cancer diagnostics using whole genome sequence and structure information. we are enabling a new era of comprehensive, clinically actionable therapy selection insight.
Aacr 2025 Arima Genomics In summary, this study demonstrates how arima hic sequencing provides molecular diagnostic value in archived pediatric solid and liquid tumor specimens via the identification of clinically relevant gene fusions. Arima genomics is redefining cancer diagnostics using whole genome sequence and structure information. we are enabling a new era of comprehensive, clinically actionable therapy selection insight.
Aacr 2022 Flagship Biosciences
Comments are closed.